List of Excipients in Branded Drug ADVIL ALLERGY AND CONGESTION RELIEF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ADVIL ALLERGY AND CONGESTION RELIEF	chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride	0573-0196	ACESULFAME POTASSIUM
Haleon US Holdings LLC	ADVIL ALLERGY AND CONGESTION RELIEF	chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride	0573-0196	CARNAUBA WAX
Haleon US Holdings LLC	ADVIL ALLERGY AND CONGESTION RELIEF	chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride	0573-0196	CELLULOSE, MICROCRYSTALLINE
Haleon US Holdings LLC	ADVIL ALLERGY AND CONGESTION RELIEF	chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride	0573-0196	CROSCARMELLOSE SODIUM
Haleon US Holdings LLC	ADVIL ALLERGY AND CONGESTION RELIEF	chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride	0573-0196	EGG PHOSPHOLIPIDS
Haleon US Holdings LLC	ADVIL ALLERGY AND CONGESTION RELIEF	chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride	0573-0196	FERRIC OXIDE RED

Excipient Strategy and Commercial Opportunities for Advil Allergy and Congestion Relief

Last updated: August 10, 2026

Advil Allergy and Congestion Relief is an OTC fixed-dose combination of ibuprofen 200 mg and pseudoephedrine hydrochloride 30 mg per caplet. Its commercial position depends more on brand recognition, regulatory compliance, packaging, supply reliability, and product experience than on active-ingredient patent exclusivity. Excipient opportunities exist in coating performance, tablet robustness, dissolution control, stability, swallowability, and differentiated packaging, but changes must preserve the established ibuprofen and pseudoephedrine release profiles.

What is the formulation of Advil Allergy and Congestion Relief?

The product combines an analgesic and antipyretic, ibuprofen, with a nasal decongestant, pseudoephedrine hydrochloride. The labeled strength is generally:

Component	Amount per caplet	Primary function
Ibuprofen	200 mg	Pain and fever reduction
Pseudoephedrine hydrochloride	30 mg	Temporary nasal and sinus decongestion

The product is marketed as an immediate-release oral caplet. The formulation is intended to deliver both active ingredients without the extended-release profile used in products such as 12-hour pseudoephedrine combinations.

Public product labeling identifies conventional tablet excipients associated with direct compression or wet granulation, film coating, flow control, disintegration, lubrication, and color. The precise inactive-ingredient list can vary by market, package size, manufacturing site, and product version. DailyMed and the current FDA-recognized labeling remain the controlling sources for a specific NDC presentation.[1]

What excipient functions are commercially important?

A practical excipient strategy for this product must address five formulation requirements:

1. Maintain rapid and reproducible release of both active ingredients.
2. Prevent tablet capping, sticking, and friability during high-speed manufacture.
3. Protect the caplet from moisture, light, and mechanical damage.
4. Produce a smooth, swallowable surface.
5. Support regulatory substitution without changing the product's safety or performance profile.

The likely formulation platform includes common pharmaceutical excipients such as microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, talc, titanium dioxide, and colorants. These materials are widely used and generally do not create strong standalone exclusivity. Their value is operational: they can reduce rejects, improve throughput, extend shelf life, and support product differentiation.

How should excipients be selected for ibuprofen and pseudoephedrine tablets?

Excipient selection should begin with active-ingredient compatibility rather than tablet appearance. Ibuprofen is a relatively high-dose, poorly water-soluble active ingredient. Pseudoephedrine hydrochloride is more water soluble and can produce a different granulation and dissolution behavior. The combination creates a formulation-balancing problem.

Direct-compression versus granulation strategy

A direct-compression formulation can reduce processing steps and solvent exposure. It requires excipients with reliable flow, compactibility, and low segregation risk. A combination tablet containing a high-dose ibuprofen component and a lower-dose pseudoephedrine component must be evaluated for blend uniformity, particularly during hopper discharge and tablet compression.

Wet granulation can improve content uniformity and compressibility, but it adds drying controls and can increase process cost. Moisture-sensitive formulations require careful control of granulation endpoint, residual moisture, and coating conditions.

A commercial formulation team would normally compare:

Formulation route	Commercial advantage	Principal risk
Direct compression	Lower process complexity and cost	Segregation and poor flow
Wet granulation	Better compactibility and uniformity	Moisture, drying, and higher cost
Separate granulation of actives	More control over each active	Greater process complexity
Roller compaction	Solvent-free densification	Recompactibility and dissolution changes

The most attractive route is the one that maintains rapid dissolution while reducing manufacturing variability. A new excipient should not be adopted solely because it improves hardness if it slows ibuprofen or pseudoephedrine release.

Flow aids and lubricants

Colloidal silicon dioxide can improve powder flow and reduce blend variability. Magnesium stearate can improve ejection and reduce tooling adhesion, but excess concentration or prolonged lubrication may reduce tablet strength and slow dissolution.

For a high-volume OTC product, lubricant optimization has direct economic value. Small reductions in sticking, picking, and tablet breakage can improve overall equipment effectiveness. The formulation should be assessed using both laboratory dissolution and commercial-scale compression data because lubricant effects often become more visible at high compression speed.

Disintegrants

Croscarmellose sodium and pregelatinized starch can support caplet breakup. Their performance depends on intragranular and extragranular placement, compression force, particle size, and tablet porosity.

A faster disintegration profile can improve onset perception, but it does not automatically produce faster clinical relief. Any formulation change should preserve the drug release specifications and avoid creating a regulatory or bioequivalence issue.

What excipient opportunities exist for a reformulated Advil Allergy and Congestion Relief?

The strongest opportunities are incremental. They target manufacturing, patient experience, and supply resilience rather than new pharmacology.

1. Improved film coating

A thinner, lower-defect film coat could reduce coating time, solvent or water use, and tablet weight. A more robust coating could reduce chipping during bottling, transportation, and consumer handling.

Potential development objectives include:

• Reduced coating weight without loss of opacity.
• Improved resistance to abrasion.
• Reduced tack during high-humidity processing.
• Better color consistency across production lots.
• Lower reliance on titanium dioxide or specific synthetic colorants where consumer preferences support reformulation.
• Improved identification of the caplet without changing the registered appearance materially.

Coating changes must be tested for moisture ingress, dissolution, stability, and packaging compatibility.

2. Better swallowability

Caplet size is a major consumer-experience variable. Ibuprofen already accounts for most of the active mass, so reducing tablet size may be difficult without changing the dosage form.

Opportunities include:

• A smoother low-friction coating.
• More rounded caplet geometry.
• Lower tablet edge sharpness.
• Optimized hardness that preserves integrity without creating excessive resistance to swallowing.
• A smaller or more compact tablet through higher-density excipients.

A smaller tablet could support premium positioning, but aggressive densification may slow disintegration or create compression defects.

3. Moisture and stability protection

Pseudoephedrine hydrochloride and ibuprofen require stability testing under ICH conditions and in the final commercial package. Moisture control is especially relevant where tablets use hygroscopic excipients or are distributed through humid markets.

Commercial options include:

• High-barrier blister films.
• Desiccant-containing bottles.
• Induction seals.
• Lower-moisture excipient grades.
• Coating systems with improved water-vapor resistance.
• Packaging that limits repeated exposure after opening.

Packaging and excipient strategy should be developed together. A more expensive barrier package may permit a simpler tablet formulation, while a robust coating and low-moisture excipient platform may reduce packaging cost.

4. Excipient substitution for supply resilience

A branded OTC product can face significant exposure to single-source excipients, colorants, coating polymers, and specialty grades. Qualification of alternate suppliers can reduce the risk of production interruption.

The highest-value substitution targets are materials that are:

• Single sourced.
• Subject to geopolitical or transport risk.
• Available in only one pharmaceutical grade.
• Critical to dissolution or tablet appearance.
• Difficult to replace without a long stability program.

Supplier qualification should include particle-size distribution, moisture, bulk density, microbiological quality, elemental impurities, residual solvents, and functional performance. A nominally identical compendial grade may not be functionally equivalent in compression or dissolution.

5. Consumer-preference reformulation

The product may support a clean-label or sensitive-consumer version using fewer colorants, alternative coating systems, or excipients perceived as more familiar. This strategy is commercially viable only if the product retains the same OTC indications, dosing instructions, appearance recognition, and manufacturing economics.

Potential claims must remain within the applicable OTC labeling framework. "Free from" claims require control of the entire formulation and manufacturing process, including processing aids and supplier materials.

What FDA regulatory constraints apply to the excipient strategy?

Advil Allergy and Congestion Relief is positioned as an OTC drug product. Ibuprofen and pseudoephedrine have established regulatory frameworks for OTC analgesic and nasal-decongestant use, subject to the applicable FDA monograph, labeling, dosage, combination, and testing requirements.[2][3]

A reformulation may be straightforward when it uses established excipients at customary levels and does not change:

• Active-ingredient strength.
• Dosage form.
• Route of administration.
• Release characteristics.
• Indications.
• Warnings.
• Directions.
• Product identity.

A more material change may require additional regulatory support. Examples include:

• Modified-release delivery.
• New dosage form.
• Significant change in dissolution.
• New inactive ingredient or novel use level.
• Change that affects bioavailability.
• New clinical or performance claims.
• Reformulation intended to support a new OTC indication.

The FDA inactive-ingredient framework does not make an excipient automatically acceptable for every use. Precedent depends on route, dosage form, concentration, and exposure. FDA’s Inactive Ingredient Database is useful for assessing prior use, but it does not replace product-specific quality and safety evaluation.[4]

What patents protect Advil Allergy and Congestion Relief?

The principal commercial protection is likely brand and trade dress rather than a strong active-ingredient patent estate. Ibuprofen and pseudoephedrine are long-established compounds, and the standard immediate-release combination is vulnerable to formulation substitution.

Are patents listed in the Orange Book?

The Orange Book primarily lists approved prescription and certain NDA products, including patent and exclusivity information for eligible products. A conventional OTC monograph product generally does not receive the same Orange Book patent-listing structure as an NDA-approved prescription drug.[5]

For this product category, the relevant protection layers are more likely to include:

Protection layer	Strategic value
ADVIL trademark	High for consumer recognition
Product trade dress	Moderate if distinctive and enforceable
Formulation patent	Potentially meaningful if a nonconventional formulation exists
Manufacturing patent	Usually narrow and difficult to enforce commercially
Packaging patent or design right	Limited to specific package architecture
Regulatory exclusivity	Generally limited for an established OTC combination
Supplier know-how	Potentially important but confidential

No conclusion should be drawn that a formulation patent protects the marketed product without reviewing current U.S. patent assignments, prosecution histories, continuation applications, and litigation records.

How strong is the patent estate for an OTC immediate-release combination?

The patent estate for a standard ibuprofen-pseudoephedrine immediate-release caplet is generally weaker than the estate for a novel extended-release system, abuse-deterrent dosage form, pediatric platform, or proprietary delivery technology.

Patentable subject matter could include:

• A defined dissolution profile.
• A multilayer tablet separating the active ingredients.
• A moisture-protective coating system.
• A novel pseudoephedrine-release mechanism.
• A specific combination of excipients producing a measurable stability benefit.
• A manufacturing process that solves a technical problem.
• A package that improves dose control or reduces misuse.

A patent claim must distinguish the product from routine formulation optimization. Claims directed only to conventional excipients at ordinary levels may face obviousness and enablement challenges.

What generic entry risks exist for Advil Allergy and Congestion Relief?

Generic and private-label competition can enter through several routes:

1. OTC monograph-compliant ibuprofen and pseudoephedrine combination products.
2. Separate ibuprofen and pseudoephedrine products used together by consumers.
3. Store-brand caplets with equivalent strengths.
4. Single-ingredient products addressing pain or congestion separately.
5. Extended-release decongestant products competing for the same consumer need.

A direct equivalent may not require a Paragraph IV challenge if the product is marketed under the OTC monograph system rather than through an abbreviated new drug application referencing an Orange Book-listed NDA. The commercial risk is therefore often faster and more price-driven than the litigation pathway associated with prescription generics.

What factors delay generic or private-label substitution?

Barriers can still arise from:

• Consumer reliance on the ADVIL brand.
• Retailer shelf-space economics.
• Controlled-sale requirements for pseudoephedrine.
• State and federal purchase restrictions.
• Product registration and listing requirements.
• Manufacturing complexity for a stable combination tablet.
• Retailer requirements for supply continuity and service levels.
• Packaging and labeling compliance.

The main vulnerability is price erosion. A private-label producer can use conventional excipients and compete if it achieves acceptable dissolution, stability, appearance, and supply economics.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have the strongest opportunity where they can demonstrate measurable performance rather than merely offer a replacement material.

High-value supplier propositions

Opportunity	Buyer value	Evidence required
Co-processed filler-disintegrant	Better compression and faster development	Flow, hardness, friability, dissolution
Low-moisture excipient grade	Stability and lower packaging burden	Water activity, accelerated stability
High-performance lubricant	Less sticking and lower ejection force	Compression data and scale-up results
Robust film-coating system	Lower defects and shorter coating cycle	Coating uniformity, abrasion, stability
Colorant replacement	Consumer and supply-chain flexibility	Color matching, regulatory status
Direct-compression platform	Lower manufacturing cost	Blend uniformity and segregation studies
Barrier coating	Improved shelf life	Moisture-vapor transmission and stability

The commercial case should quantify reduced scrap, lower cycle time, fewer deviations, longer shelf life, or lower total landed cost. A 1% improvement in yield can matter more than a modest reduction in excipient price for a high-volume OTC product.

Licensing and collaboration opportunities

Potential licensing structures include:

• Nonexclusive excipient supply agreements.
• Preferred-supplier contracts.
• Joint development of a coating or compression platform.
• Technology licenses for multilayer or modified-release systems.
• Regional manufacturing licenses.
• Co-development of retailer-specific or pharmacy-channel presentations.

For a mature OTC brand, the most realistic deal is often a supply-and-development agreement rather than a royalty-bearing license on a single excipient. A proprietary formulation platform becomes more valuable if it can support several products in the Advil, cold-and-flu, or sinus portfolio.

How does Advil Allergy and Congestion Relief compare with competing products?

Product category	Core actives	Excipient opportunity	Competitive pressure
Ibuprofen-pseudoephedrine combination	Analgesic plus decongestant	Compact caplet, fast disintegration, packaging	Direct private-label substitution
Ibuprofen-only product	Ibuprofen	Smaller tablet, coating, chewable format	Lower price and broader use
Pseudoephedrine-only product	Pseudoephedrine	Extended-release matrix, tablet size	Decongestion-focused consumers
Acetaminophen-pseudoephedrine product	Acetaminophen plus decongestant	Alternative analgesic platform	Different safety and consumer profile
Multi-symptom cold product	Multiple actives	Taste, capsule, coating, and dose architecture	Broad indication and strong shelf presence

The principal competitive advantage of the ibuprofen-pseudoephedrine combination is convenience. The principal technical disadvantage is formulation complexity relative to a single-ingredient product.

What generic launch scenarios should manufacturers expect?

Scenario 1: Immediate private-label replication

A retailer or contract manufacturer launches an equivalent-strength caplet using conventional excipients. This is the most direct threat. Price, shelf placement, and packaging recognition determine uptake.

Scenario 2: Premium formulation differentiation

A competitor launches a smaller, smoother, easier-to-swallow caplet or a more moisture-resistant blister presentation. The active ingredients remain unchanged, but the product competes on experience and convenience.

Scenario 3: Modified-release substitution

A competitor uses extended-release pseudoephedrine or a different dosing schedule. This does not replicate the product exactly but may capture consumers seeking longer duration.

Scenario 4: Portfolio substitution

Retailers promote separate ibuprofen and pseudoephedrine products, especially where inventory or pricing makes separate products more attractive. This weakens the convenience advantage of the combination product.

What geographic and manufacturing barriers affect the opportunity?

Pseudoephedrine is subject to controlled-sale requirements in the United States, including purchase tracking and quantity limits under federal law.[6] These controls affect distribution, inventory management, retail execution, and cross-border commercialization.

Manufacturing barriers include:

• Controlled-substance handling and recordkeeping requirements where applicable.
• Qualified suppliers for pharmaceutical-grade pseudoephedrine hydrochloride.
• Segregated inventory and security controls.
• Labeling compliance across countries.
• Different allowable excipients and colorants by jurisdiction.
• Country-specific OTC monograph or registration pathways.
• Import and serialization requirements.
• Stability expectations for hot and humid climates.

A formulation optimized for the United States may require separate excipient, package, or label configurations in Europe, Canada, Asia-Pacific, and Latin America.

Key Takeaways

• Advil Allergy and Congestion Relief is an immediate-release combination of ibuprofen 200 mg and pseudoephedrine hydrochloride 30 mg per caplet.
• The principal formulation challenge is balancing ibuprofen’s high dose and low solubility with pseudoephedrine’s higher solubility and rapid-release requirements.
• The best excipient opportunities are improved coating, compression, disintegration, moisture protection, swallowability, and alternate-supplier qualification.
• Conventional excipients are unlikely to create significant standalone exclusivity. Proprietary performance must be demonstrated through measurable manufacturing or stability benefits.
• OTC monograph positioning reduces reliance on Orange Book exclusivity and increases exposure to rapid private-label competition.
• Brand, trade dress, retail placement, supply reliability, and packaging are likely more important commercial defenses than active-ingredient patents.
• Excipient suppliers should sell total manufacturing value, including yield, cycle time, stability, and defect reduction.
• Pseudoephedrine controls create distribution and retail barriers that affect U.S. commercialization and generic launch timing.

FAQs

Can a new excipient create a new patent position for Advil Allergy and Congestion Relief?

Yes, but only if the formulation produces a technically meaningful and non-obvious result, such as improved stability, a defined release profile, or a manufacturing benefit that is supported by comparative data.

Is a chewable version commercially attractive?

It could expand use among consumers who have difficulty swallowing caplets, but ibuprofen taste, pseudoephedrine taste, dose size, and pediatric safety requirements create substantial formulation and regulatory constraints.

Would a blister package improve the product’s competitive position?

A blister may improve dose protection, portability, and moisture control. Its commercial value depends on packaging cost, child-resistance requirements, consumer convenience, and retailer preferences.

Can an excipient change trigger new FDA testing?

Yes. A significant inactive-ingredient change, novel excipient, altered dosage form, or change in dissolution or bioavailability can require additional quality, stability, safety, or bioequivalence support.

Is pseudoephedrine controlled in every country?

No. Controls vary by jurisdiction. The United States imposes federal retail and purchase restrictions, while other countries may classify pseudoephedrine as prescription-only, pharmacy-only, or subject to import and quantity controls.

References

1. National Library of Medicine. (n.d.). DailyMed: Advil Allergy and Congestion Relief labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
3. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Drug Enforcement Administration. (2024). Combat Methamphetamine Epidemic Act and retail sales requirements for pseudoephedrine.